ArticleBMC pregnancy and childbirth2026
Novel inflammatory markers for predicting adverse pregnancy outcomes in pregnant women with polycystic ovary syndrome: a retrospective case‒control study.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the potential predictive value of novel inflammatory markers for adverse pregnancy outcomes in pregnant women with polycystic ovary syndrome (PCOS).
methodsA retrospective case‒control study was conducted. Clinical data were collected from pregnant PCOS patients and healthy pregnant women who received regular prenatal care and delivered at our hospital between 2021 and 2023. All included subjects had relevant clinical data collected. Basic characteristics, novel inflammatory markers, and adverse pregnancy outcomes were compared between the two groups. A random forest classification model was applied to evaluate the potential predictive value of combined novel inflammatory markers for adverse pregnancy outcomes in women with PCOS.
resultsA total of 528 pregnant women were included. Compared with those in the control group, pregnant women in the PCOS group demonstrated statistically significant differences in height, first-trimester body mass index (BMI), gestational weight gain, BMI at admission, systolic blood pressure (SBP) at admission, and diastolic blood pressure (DBP) at admission (P < 0.05). Among participants with adverse pregnancy outcomes, compared with the control group, the PCOS group had an increased monocyte-to-lymphocyte ratio (MLR) (0.29 ± 0.02), neutrophil-to-lymphocyte ratio (NLR) (3.56 ± 0.21), systemic inflammation response index (SIRI) (1.98 ± 0.19), platelet-to-lymphocyte ratio (PLR) (133.76 ± 5.26), and systemic immune inflammation index (SII) (834.27 ± 55.72) (P < 0.05). After adjusting for confounding factors and optimizing hyperparameters, the combined prediction model using these five novel inflammatory markers (MLR, NLR, SIRI, PLR, and SII) achieved an AUC of 0.815, an F1 score of 0.776, an accuracy of 79.40%, and a precision of 79.40% for adverse pregnancy outcomes in patients with PCOS.
conclusionEvaluation via the random forest classification model revealed that the combined use of these novel inflammatory markers has potential predictive value for adverse pregnancy outcomes in pregnant women with PCOS. These findings merit attention from clinical practitioners, and corresponding preventive measures should be implemented.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.